

Press Release:

Halamid® Aqua gains exclusive animal drug status

May 6 2014, Bouc Bel Air

Axcentive Sarl, with its headquarters located in France, is proud to announce that on May 6 the FDA's Center for Veterinary Medicine (CVM) has awarded a New Animal Drug Application (NADA) approval to Axcentive for the use of Halamid® Aqua in aquaculture throughout the USA. The approval covers 3 label claims: control of mortality in (1) all freshwater-reared salmonids due to bacterial gill disease, (2) walleye due to external columnaris disease and (3) all freshwater-reared warm water finfish due to external columnaris disease. Halamid® Aqua is available in 25 kg drums and 5 kg buckets.

Paul Raadsen, Executive Director at Axcentive comments:

"A key factor in the success of this project has been the cooperation between many agencies and organizations such as the Federal-State Aquaculture Drug Approval Partnership Project, the Aquatic Animal Drug Approval Partnership Program, the Upper Midwest Environmental Sciences Center, the National NADA Coordinator (currently Roz Schnick Consulting, LLC) and Axcentive."

The sponsor, Axcentive Sarl, funded a part of the studies done by other research institutes, completed the requirements for toxicology, environmental safety, microbial food safety, and chemistry, manufacturing and controls. After many years of effort, Axcentive completed the requirements for all major and minor technical sections which led to the final submission and approval of the Administrative NADA.

Paul Raadsen continues, "This is an important approval for the US aquaculture industry. Halamid® Aqua will be:

- The 2nd waterborne drug approved for disease claims for finfish in almost 30 years
- The 3rd aquaculture drug with an original approval covering multiple label claims for use in a variety of finfish species, and
- The 4th aquaculture drug to gain NADA approval under the Minor Use and Minor Species
 Animal Health Act, entitling Axcentive SARL to seven years of exclusive marketing rights for
 the approved label claims.

All participants involved are to be congratulated for their major contributions to this significant approval. A very special thank you goes to past and current staff at CVM for the tremendous guidance they provided and the encouragement they gave us while we were going through the approval process."

Axcentive - the outcome of a Management buy-out of Akzo Nobel's Sulfo products group provides specialty products based on sulfonamide chemistry. Its products are used in disinfectants, pharmaceutical synthesis and specialty coatings additives. The company supplies products worldwide under the Halamid, Ketjenflex and Ketjensept brand names. For further information about Halamid® Aqua, interested parties should contact Western Chemical Inc., Ferndale WA, the exclusive US distributor of the product, at 800-283-5292, email to: info@wchemical.com or visit their website at www.wchemical.com. Ends.